INTRODUCTION {#s1}
============

Lung cancer is the most common malignant cancer and the leading cause of cancer death worldwide \[[@R1]\]. Surgery with or without postoperative radiochemotherapy is the standard therapy for operable non-small cell lung cancer (NSCLC) patients with stage I-III A \[[@R2], [@R3]\]. For non-operable NSCLC patients, chemotherapy, targeted therapy, radiotherapy and their combination are utilized \[[@R4], [@R5]\]. Natural innate and adaptive immunity play important roles in cancer development and interact with cancer therapeutics \[[@R6], [@R7]\]. Based on this mechanism, we hypothesized that the pretreatment systemic immune status could influence the effects of cancer therapeutics and consequently affect patients' clinical outcomes. Many studies have investigated the prognostic value of CD4+ T cells, CD8+ T cells, regulatory T cells and B cells \[[@R8]--[@R12]\]. Nevertheless, very little is known of the predictive roles of peripheral naïve T cells, memory T cells and CD45RA+CD45RO+ T cells in NSCLC patients.

CD45RA+ T cells are identified as naïve T lymphocytes that have not responded to antigen; they will be activated by the stimulation of antigen and differentiate to effector cells against tumor cells. CD45RO is the marker of memory T lymphocytes which have responded to tumor antigen and will solicit immune response by the re-exposure of antigen \[[@R13]--[@R15]\]. T cells coexpressing CD45RA and CD45RO are special cells in the process of transformation from naïve cells to memory cells \[[@R16]\]. Hara et al. \[[@R17]\] found no differences in the proportions of naïve CD4+ T cells, memory CD4+ T cells, and the CD4+ naïve/memory ratios between NSCLC patients and healthy controls. Similarly, there were no significant differences of naïve CD8+ cells and memory CD8+ cells \[[@R18]\]. Two very recent studies proved that high levels of CD45RO (+) tumor-infiltrating lymphocytes were associated with better survival in lung cancer patients \[[@R19], [@R20]\].

Thus, the purpose of this study was to investigate the clinical significance of peripheral naïve T cells, memory T cells, CD45RA+CD45RO+ T cells and naïve/memory ratio in NSCLC patients.

RESULTS {#s2}
=======

Clinicopathologic characteristics {#s2_1}
---------------------------------

Clinicopathologic characteristics of 76 NSCLC patients are shown in Table [1](#T1){ref-type="table"}. Among them, 41 received radical surgery and 35 were treated with radiotherapy combined with chemotherapy/targeted therapy. Tumors with epidermal growth factor receptor (EGFR) mutation occurred in 4 patients; anaplastic lymphoma kinase (ALK) gene fusion occurred in 2 patients. nineteen patients had evidence of distant metastases at diagnosis; there were 5 with lung metastases, 3 with brain metastases, 6 with bone metastases, and 5 with adrenal metastasis.

###### Clinicopathologic characteristics of 76 NSCLC patients

  Parameter                  N=76(%)
  -------------------------- -------------
  Age(years)                 64.5(35-87)
  Gender                     
   Male                      54(71.1)
   Female                    22(28.9)
  ECOG                       
   0                         32(42.1)
   1-2                       44(57.9)
  Smoking history            
   Yes                       50(65.8)
   No                        26(34.2)
  Histology                  
   Squamous cell carcinoma   37(48.7)
   Adenocarcinoma            39(51.3)
  Differentiation            
   Well/moderate             48(63.2)
   Poor                      23(30.3)
   Unknown                   5(6.5)
  T stage                    
   1                         20(26.3)
   2                         32(42.1)
   3                         11(14.5)
   4                         13(17.1)
  N stage                    
   0                         21(27.6)
   1                         24(31.6)
   2                         19(25.0)
   3                         12(15.8)
  Clinical stage (TNM)       
   I                         8(10.5)
   II                        16(21.1)
   III                       33(43.4)
   IV                        19(25.0)

NSCLC=non-small cell lung cancer, ECOG=Eastern Cooperative Oncology Group.

The expression of immune cells in 76 NSCLC patients {#s2_2}
---------------------------------------------------

Lung cancer patients expressed significantly decreased proportions of naïve CD4+ T cells, naïve CD8+ T cells, CD4+ naïve/memory ratios, and CD4+CD45RA+CD45RO+ T cells and increased memory CD4+ T cells compared to healthy controls (Figure [1](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). In addition, a similar trend occurred in CD8+ naïve/memory ratios, CD8+CD45RA+CD45RO+ T cells and memory CD8+ T cells, but the differences did not reach statistical significance.

![Differences in the proportions of CD45RA and CD45RO marked T cells between NSCLC patients and healthy controls\
In NSCLC, there are **(A)** decreased naïve CD4+ T cells and CD4+CD45RA+CD45RO+ T cells, and increased memory CD4+ T cells; **(B)** reduced naïve CD8+ T cells; **(C)** low CD4+ naïve/memory ratio. ^\*^*P* \< 0.05; ^\*\*^ *P* \< 0.01.](oncotarget-08-83650-g001){#F1}

###### Differences of immune cells between NSCLC patients and healthy volunteers

  Variable                  Healthy volunteers   NSCLC         *P-value*
  ------------------------- -------------------- ------------- -----------
  Naïve CD4+                44.26±12.21          31.46±15.26   0.002
  Memory CD4+               71.52±12.35          79.83±13.71   0.025
  CD4+CD45RA+CD45RO+        15.85±5.32           11.38±4.49    0.001
  CD4+ naïve/memory ratio   0.67±0.31            0.44±0.34     0.009
  Naïve CD8+                70.66±7.62           61.15±15.02   0.045
  Memory CD8+               53.35±14.35          57.03±16.3    0.451
  CD8+CD45RA+CD45RO+        24.06±10.46          20.28±7.79    0.117
  CD8+ naïve/memory ratio   1.46±0.57            1.30±0.73     0.450

NSCLC=non-small cell lung cancer, SD=standard deviation.

Correlation of immune cells with clinicopathologic characteristics {#s2_3}
------------------------------------------------------------------

Table [3](#T3){ref-type="table"} summarizes the relationships between immune cells and clinicopathological characteristics in the 76 NSCLC patients. In never-smokers, high proportions of naïve CD4+ T cells and low memory CD4+ T cells were observed. Similarly, there was a trend in younger patients for these findings although they did not achieve statistical significance. In patients with good performance status, decreased naïve CD8+ T cells and CD8+ naïve/memory and increased memory CD8+ T cells were found.

###### Associations between immune parameters and clinicopathologic parameters in 76 NSCLC patients

  Variable               Naïve CD4+    Memory CD4+   CD4+CD45RA+CD45RO+   CD4+ naïve/memory ratio   Naïve CD8+   Memory CD8+   CD8+CD45RA+CD45RO+   CD8+ naïve/memory ratio                                                                                
  ---------------------- ------------- ------------- -------------------- ------------------------- ------------ ------------- -------------------- ------------------------- ------------- ------- ------------- ------- ------------ ------- ----------- -------
  Age(years)                                                                                                                                                                                                                                               
  \<64.5                 39.15±15.40   0.051         73.47±14.97          0.062                     12.69±5.29   0.377         0.61±0.41            0.056                     65.32±19.40   0.216   54.43±19.64   0.173   19.82±6.18   0.646   1.52±1.00   0.054
  ≥64.5                  28.90±14.19                 82.32±12.13                                    11.29±4.01                 0.39±0.26                                      58.80±11.73           62.21±13.77           21.08±8.67           1.03±0.45   
  Gender                                                                                                                                                                                                                                                   
  Female                 35.98±12.98   0.417         76.77±11.68          0.531                     12.84±4.26   0.396         0.50±0.26            0.685                     58.98±18.76   0.597   59.49±20.45   0.984   18.53±5.79   0.324   1.22±0.78   0.97
  Male                   31.30±16.09                 80.03±14.52                                    11.4±4.59                  0.45±0.37                                      61.99±13.66           59.36±14.88           21.43±8.40           1.21±0.72   
  ECOG                                                                                                                                                                                                                                                     
  0                      30.52±11.86   0.547         80.94±10.46          0.557                     11.53±4.65   0.794         0.40±0.22            0.395                     53.54±14.29   0.020   67.86±13.50   0.017   21.48±6.81   0.626   0.85±0.34   0.007
  1-2                    33.77±17.02                 78.09±15.37                                    11.95±4.50                 0.50±0.39                                      65.46±13.92           54.62±16.03           20.14±8.41           1.41±0.81   
  Smoking history                                                                                                                                                                                                                                          
  No                     41.13±13.95   0.024         72.51±12.87          0.053                     13.69±5.08   0.093         0.61±0.29            0.084                     66.68±19.77   0.146   54.82±22.44   0.269   21.55±8.55   0.646   1.58±1.04   0.042
  Yes                    28.84±14.51                 82.03±13.27                                    10.96±4.03                 0.40±0.34                                      58.72±12.08           61.41±12.80           20.22±7.59           1.05±0.48   
  Histology                                                                                                                                                                                                                                                
  SCC                    27.51±14.20   0.102         82.7±11.53           0.246                     10.29±4.55   0.054         0.36±0.24            0.138                     58.25±14.52   0.447   62.86±14.35   0.394   21.18±8.57   0.772   1.03±0.51   0.282
  ADC                    35.82±14.59                 77.3±15.05                                     13.20±3.84                 0.53±0.40                                      62.15±14.97           58.14±17.47           20.37±7.54           1.29±0.85   
  Differentiation                                                                                                                                                                                                                                          
  Well/Moderate          33.56±15.52   0.243         78.39±13.83          0.281                     12.02±5.15   0.544         0.49±0.37            0.325                     60.44±15.45   0.643   60.95±15.50   0.614   21.48±7.97   0.850   1.12±0.56   0.332
  Poor                   26.03±14.61                 84.69±13.99                                    10.82±3.12                 0.35±0.28                                      63.38±14.41           57.43±19.92           20.83±8.98           1.41±1.08   
  T stage                                                                                                                                                                                                                                                  
  1                      30.23±14.90   0.626         82.92±11.79          0.381                     13.25±5.70   0.307         0.40±0.29            0.517                     63.24±14.19   0.662   54.33±17.17   0.326   17.71±8.14   0.235   1.35±0.74   0.536
  2-4                    33.28±15.56                 78.03±14.21                                    11.38±4.11                 0.49±0.35                                      60.56±15.45           60.85±16.07           21.46±7.64           1.17±0.73   
  N stage                                                                                                                                                                                                                                                  
  0                      31.93±16.66   0.882         80.65±16.09          0.705                     12.71±5.64   0.491         0.48±0.48            0.893                     61.06±11.55   0.982   57.93±15.06   0.760   19.17±7.34   0.524   1.17±0.52   0.850
  1-3                    32.82±15.10                 78.61±13.12                                    11.49±4.12                 0.46±0.29                                      61.19±16.21           59.89±16.94           21.11±8.01           1.22±0.79   
  Clinical stage (TNM)                                                                                                                                                                                                                                     
  I-III                  31.59±13.75   0.556         79.85±11.23          0.636                     11.52±5.02   0.582         0.43±0.25            0.310                     61.42±15.38   0.875   59.49±15.90   0.960   20.99±8.45   0.676   1.18±0.63   0.757
  IV                     34.90±18.78                 77.46±18.71                                    12.43±3.06                 0.55±0.48                                      60.55±14.87           59.19±17.98           19.79±6.34           1.27±0.94   

NSCLC=non-small cell lung cancer, SD=standard deviation, ECOG=Eastern Cooperative Oncology Group, SCC=squamous cell carcinoma, ADC=adenocarcinoma.

Increased CD4+ naïve/memory ratio associated with better progression-free survival {#s2_4}
----------------------------------------------------------------------------------

Univariate analysis of immune parameters and clinicopathologic parameters are shown in Table [4](#T4){ref-type="table"}. Interestingly, patients with a high level of CD4+ naïve/memory ratio had a better PFS (HR = 0.47, 95%CI = 0.20-0.92, *P* = 0.013, Figure [2A](#F2){ref-type="fig"}). In contrast, elevated CD4+CD45RA+CD45RO+ T cells predicted poor PFS with a robust trend toward significance (HR = 2.71, 95%CI = 1.15-6.36, *P* = 0.058, Figure [2B](#F2){ref-type="fig"}). Besides, patients with an increase of memory CD4+ T cells may have a poor PFS (HR = 1.82, 95%CI = 0.78-4.25, *P* = 0.138, Table [4](#T4){ref-type="table"}).

###### Progression free survival of 76 NSCLC patients stratified by immune parameters and clinicopathologic parameters

  Variable                  Median survival (months)   HR (95%CI)         *P-value*
  ------------------------- -------------------------- ------------------ -----------
  Naïve CD4+                                                              
   \<median                 10                         1                  0.583
   ≥median                  13                         0.80(0.35-1.85)    
  Memory CD4+                                                             
   \<median                 15                         1                  0.138
   ≥median                  9                          1.82(0.78-4.25)    
  CD4+CD45RA+CD45RO+                                                      
   \<12.5                   15                         1                  0.058
   ≥12.5                    9                          2.71(1.15-6.36)    
  CD4+ naïve/memory ratio                                                 
   \<0.34                   9                          1                  0.013
   ≥0.34                    17                         0.47(0.20-0.92)    
  Naïve CD8+                                                              
   \<median                 13                         1                  0.808
   ≥median                  13                         1.11(0.47-2.59)    
  Memory CD8+                                                             
   \<median                 13                         1                  0.726
   ≥median                  13                         1.15(0.50-2.67)    
  CD8+CD45RA+CD45RO+                                                      
   \<median                 12                         1                  0.806
   ≥median                  15                         0.90(0.39-2.11)    
  CD8+ naïve/memory ratio                                                 
   \<median                 13                         1                  0.567
   ≥median                  13                         0.79(0.34-1.84)    
  Gender                                                                  
   Female                   15                         1                  0.156
   Male                     12                         1.85(0.68-6.35)    
  Age(years)                                                              
   \<64.5                   13                         1                  0.682
   ≥64.5                    15                         0.86(0.29-1.58)    
  Smoking status                                                          
   No                       15                         1                  0.583
   Yes                      13                         1.25(0.68-3.15)    
  Differentiation                                                         
   Well and moderate        15                         1                  0.006
   Poor                     9                          3.95(2.35-12.37)   
  ECOG                                                                    
   0                        17                         1                  0.018
   1-2                      12                         3.46(1.28-8.24)    
  T stage                                                                 
   1                        15                         1                  0.482
   2-4                      13                         1.82(0.79-6.25)    
  N stage                                                                 
   0                        17                         1                  0.026
   1-3                      13                         3.28(1.13-9.67)    
  Clinical stage (TNM)                                                    
   I-III                    15                         1                  0.004
   IV                       9                          3.68(1.45-8.47)    

NSCLC=non-small cell lung cancer, HR=hazard ratio, CI=confidence interval, ECOG=Eastern Cooperative Oncology Group performance status.

![Progression-free survival of 76 NSCLC patients stratified by **(A)** CD4+ naïve/memory ratio; **(B)** CD4+CD45RA+CD45RO+ T cells.](oncotarget-08-83650-g002){#F2}

In addition to immune parameters, we found other parameters associated with clinical outcomes. Tumor differentiation, nodal stage, clinical stage and the Eastern Cooperative Oncology Group performance status correlated with the patients' clinical outcome (Table [4](#T4){ref-type="table"}).

CD4+ naïve/memory ratio independently correlated with progression-free survival {#s2_5}
-------------------------------------------------------------------------------

Multivariate cox proportional hazard models revealed that increased CD4+ naïve/memory ratio was independently associated with better PFS (HR = 0.35, 95%CI = 0.19-0.75, *P* = 0.012, Table [5](#T5){ref-type="table"}). In addition, nodal stage and clinical stage were independently correlated with the progression-free survival of 76 NSCLC patients.

###### Multivariate cox proportional hazard models for progression free survival of 76 NSCLC patients

  Variable                     HR      95%CI        *P-value*
  ---------------------------- ------- ------------ -----------
  N stage                                           
   1-3 vs 0                    10.79   2.43-47.85   0.002
  Clinical stage                                    
   IV vs I-III                 4.61    1.34-15.91   0.016
  ECOG                                              
   1-2 vs 0                    2.77    0.82-9.35    0.135
  Differentiation                                   
   Poor vs Well and moderate   3.34    0.84-13.33   0.087
  CD4+ naïve/memory ratio                           
   ≥0.34 vs \<0.34             0.35    0.19-0.75    0.012

NSCLC=non-small cell lung cancer, ECOG=Eastern Cooperative Oncology Group.

DISCUSSION {#s3}
==========

To the best of our knowledge, this is a study with the largest sample size to investigate the predictive roles of peripheral naïve/memory ratio, naïve cells, memory cells, and CD45RA+CD45RO+ T cells in patients with NSCLC. The most important findings were that elevated CD4+ naïve/memory ratio was independently correlated with prolonged PFS. Moreover, lower percentages of naïve CD4+ T cells, naïve CD8+ T cells, CD4+ naïve/memory ratios, and CD4+CD45RA+CD45RO+ T cells, and increased memory CD4+ T cells, occurred in NSCLC patients compared to healthy controls.

Hara et al. \[[@R17]\] investigated the correlation between CD4+ naïve/memory ratio and survival after surgery in NSCLC patients and proved this possible relationship; however, there were only 8 patients in each group. In the present study, we found that elevated CD4+ naïve/memory ratio was independently associated with prolonged PFS in NSCLC patients; elevated peripheral memory CD4+ cells may indicate poor survival, which is contrary to the role of CD45RO+ tumor-infiltrating lymphocytes in tumor tissues \[[@R19]--[@R21]\]. Several possibilities may explain above phenomena. First, in tumor tissues, memory cells elicited robust immune response to attack tumor cells \[[@R13]\]. However, memory CD4+ cells in peripheral blood showed lower proliferation than primary responding cells when they re-encountered antigen and failed to elicit robust immune response \[[@R22]--[@R24]\]. In contrast, naïve T cells were more capable of proliferation and anti-tumor efficiency \[[@R25]\]. Besides, high levels of CD45RO+ tumor-infiltrating lymphocytes were associated with low tumor stage and invasion \[[@R26]\]. Correlations between elevated CD4+CD45RA+CD45RO+ cells and poor survival were observed with a trend in univariate analysis. CD4+CD45RA+CD45RO+ cells transitioned from naïve to memory cells after stimulation by tumor antigen; increased proportions of these cells may suggest higher tumor malignancy and invasion.

Furthermore, we found no predictive roles of naïve CD8+ T cells, memory CD8+ T cells, CD8+ naïve/memory ratio, and CD8+CD45RA+CD45RO+ T cells, which agrees with previous studies \[[@R17], [@R18]\]. Decreased percentages of naïve CD4+ T cells, naïve CD8+ T cells, CD4+ naïve/memory ratios, and CD4+CD45RA+CD45RO+ T cells and increased memory CD4+ T cells were observed in NSCLC patients, suggesting that the immune system was activated against cancer. A previous study has not found these results with statistical significance, which may have been accounted for by the small number of patients and early tumor grade \[[@R17]\]. In nonsmokers and young patients, increased percentages of naïve CD4+ T cells and decreased memory CD4+ T cells were observed, which were consistent with tumor characteristics of these patients.

The limitations of this study include small sample size, different clinical stages, different treatment strategies and a short follow-up time that results in the lack of detailed information on overall survival. Despite these weaknesses, we documented that CD4+ naïve/memory ratio independently predicted tumor progression. Moreover, decreased proportions of naïve CD4+ T cells, naïve CD8+ T cells, CD4+ naïve/memory ratio and CD4+CD45RA+CD45RO+ T cells, and increased memory CD4+ T cells were observed in NSCLC patients compared to healthy controls.

In summary, peripheral CD4+ naïve/memory ratio may provide an independent predictor of tumor progression in NSCLC patients. This information may provide opportunities to select NSCLC patients who would have poor survival, and optimize treatment strategies for them.

MATERIALS AND METHODS {#s4}
=====================

Patients selection {#s4_1}
------------------

We prospectively included 76 NSCLC patients with histological confirmation, who were treated in Linyi People\'s Hospital. The inclusion criteria for patients were as follows: They had not received anti-tumor therapies or other therapies that influence patients' immune status before enrollment and were over 18 years old; they had no infections, other cancers, immune system related diseases or transplant history. Twenty-eight age- and sex-matched healthy volunteers were included. Clinicopathologic characteristics of the enrolled NSCLC patients were collected from the electronic medical record system in our hospital. Clinical stage was evaluated by American Joint Committee on Cancer-7 criteria. Informed consent was obtained from all patients and volunteers. The present study was approved by the Ethical Committee of Linyi People\'s Hospital. All methods in the present study were approved by the committee and performed in accordance with relevant guidelines and regulations.

Treatment protocol and follow-up {#s4_2}
--------------------------------

Early stage patients received radical surgery and lymph node dissection; advanced patients received radiotherapy combined with chemotherapy/targeted therapy concurrently or consecutively. First-line chemotherapy was with platinum-based agents; gefitinib, erlotinib, and crizotinib were used for targeted therapy. Radiotherapy was delivered with 60-66 Gy/30-33 fractions by linear accelerator. Patients were followed up regularly per 3 months after treatment. Follow-up data collection ended on April 16, 2017 or the time of death of the patient. The median follow-up was 13 months (range 6-22.5 months). The primary endpoint was PFS, which was defined as the interval between the date of initial therapy and the date of the first RECIST- (Response Evaluation Criteria in Solid Tumors) 1.1 \[[@R27]\] defined progression, death, or loss to follow-up.

Detection of immune cells {#s4_3}
-------------------------

Fresh peripheral blood samples obtained from patients prior to cancer treatment and from volunteers were stored in EDTA anticoagulation tubes before testing. Four specific monoclonal antibodies (mAbs) against CD4 (FITC and APC), CD8 (FITC and APC), CD45RA (FITC), CD45RO (PE) were used to differentiate immune cells. Initially, 200μl blood was mixed with the above mAbs and incubated in the dark at room temperature. By using FACS lysing solution (BD Biosciences, San Jose, CA, USA), red blood cells in the mix were lysed and then washed twice with phosphate buffered saline (PBS). The residual white blood cells were analyzed by flow cytometry and the percentages of these immune cells were calculated by FlowJo Version 10.0 data analysis software (FlowJo, Ashland, OR, USA).

Immune cells were identified as follow: naïve CD4+ T cells (CD4+CD45RA+), memory CD4+ T cells (CD4+CD45RO+), naïve CD8+ T cells (CD8+CD45RA+), memory CD8+ T cells (CD8+CD45RO+), CD4+CD4 5RA+CD45RO+ T cells (CD4+CD45RA+CD45RO+) and CD8+CD45RA+CD45RO+ T cells (CD8+CD45RA+ CD45RO+). The percentages of immune cells were expressed as proportions of CD4+/CD8+ T cells.

Statistical analysis {#s4_4}
--------------------

Percentages of immune cells were expressed with mean±standard deviation (SD). Differences of immune cells between NSCLC patients and controls, and relationships between patient characteristics and immune cells were determined by the Student\'s *t*-test. The Kaplan-Meier analysis was employed to estimate PFS and compare PFS between groups by log-rank test. The Cox proportional hazards model was performed to determine hazard ratios (HRs) and 95% confidence intervals (CIs). Variables of *P* \< 0.05 in univariate analysis were enrolled in multiple analysis. Data analyses were performed using the Statistical Package for Social Sciences, Version 22.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Version 5.0 (GraphPad Software Inc., San Diego, CA, USA); *P* \< 0.05 was defined as statistically significant.
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